Report cover image

Polycystic Ovary Syndrome Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147018

Description

Polycystic ovary syndrome (PCOS) is a hormonal disorder characterized by irregular menstrual cycles, excess androgen levels, and polycystic ovaries. It affects 8% to 13% of reproductive-age women, with up to 70% remaining undiagnosed worldwide. The disease contributes to infertility, metabolic complications, and mental health issues, highlighting a significant unmet clinical need for better therapies. Current treatments, such as hormonal contraceptives and insulin sensitizers, often provide limited relief. However, the rising focus on personalized medicine and innovative drug discovery is expected to drive pipeline growth, offering hope for more effective, targeted treatments in the coming years.

Report Coverage

The Polycystic Ovary Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into polycystic ovary syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for polycystic ovary syndrome. The polycystic ovary syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The polycystic ovary syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with polycystic ovary syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to polycystic ovary syndrome.

Polycystic Ovary Syndrome Drug Pipeline Outlook

Polycystic ovary syndrome is a hormonal disorder that occurs when there is an imbalance in reproductive hormones, leading to irregular menstrual cycles, ovarian cysts, and elevated androgen levels. This imbalance can cause infertility, metabolic issues, and other symptoms such as excess hair growth and acne.

Treatments for polycystic ovary syndrome aim to manage symptoms. Birth control pills regulate menstrual cycles, while insulin sensitizers address metabolic issues. For fertility, ovulation-inducing medications like clomiphene are used, and treatment is tailored to the individual’s symptoms and needs.

Polycystic Ovary Syndrome Epidemiology

A 2024 systematic review and meta-analysis on the prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents reveals a global prevalence of 9.8%. Regional variations include 2.9% in the Western Pacific to 11.4% in South-East Asia. This epidemiological data highlights the importance of addressing diagnosis accuracy and raising awareness for better management across regions.

Polycystic Ovary Syndrome Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of polycystic ovary syndrome drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Biologics
  • Peptide-based Drugs
  • Gene and RNA-based Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Polycystic Ovary Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I covers a major share of the total polycystic ovary syndrome clinical trials.

Polycystic Ovary Syndrome – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the polycystic ovary syndrome pipeline analysis include small molecules, biologics, peptide-based drugs, and gene- and RNA-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for polycystic ovary syndrome.

Polycystic Ovary Syndrome Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR polycystic ovary syndrome report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in polycystic ovary syndrome clinical trials:
  • Fujian Shengdi Pharmaceutical Co., Ltd.
  • Abbott Laboratories
  • AbbVie
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Sanofi SA
Polycystic Ovary Syndrome Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for polycystic ovary syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of polycystic ovary syndrome drug candidates.

Drug: Semaglutide 1.34 mg/mL

A Phase 4 study sponsored by Peking University First Hospital aims to evaluate the efficacy of semaglutide in improving metabolic abnormalities and fertility in obese, infertile women with polycystic ovary syndrome (PCOS). The trial includes 75 participants and compares metformin, semaglutide, and their combination alongside lifestyle modifications. The study is expected to conclude by June 2025 and assess weight loss and fertility-related outcomes.

Drug: HRS9531

Fujian Shengdi Pharmaceutical Co., Ltd. is sponsoring a Phase 2 multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of HRS9531 injection in obese subjects with polycystic ovary syndrome (PCOS). The study, enrolling 144 participants, began in September 2024 and is expected to be completed by December 2025, addressing critical treatment gaps in PCOS management.

Biological: AlloRx

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine, this Phase 1 study aims to evaluate the safety and efficacy of cultured allogeneic adult umbilical cord-derived mesenchymal stem cells (UCDSC) for treating polycystic ovary syndrome (PCOS). The study is expected to be completed by November 2027, with an estimated 20 participants, assessing hormone levels and ultrasound outcomes at 3-, 6-, and 12-months post-treatment.

Reasons To Buy This Report

The Polycystic Ovary Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for polycystic ovary syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within polycystic ovary syndrome pipeline insights.

Key Questions Answered in the Polycystic Ovary Syndrome – Pipeline Insight Report
  • Which companies/institutions are leading the polycystic ovary syndrome drug development?
  • What is the efficacy and safety profile of polycystic ovary syndrome pipeline drugs?
  • Which company is leading the polycystic ovary syndrome pipeline development activities?
  • What is the current polycystic ovary syndrome commercial assessment?
  • What are the opportunities and challenges present in the polycystic ovary syndrome drug pipeline landscape?
  • What is the efficacy and safety profile of polycystic ovary syndrome pipeline drugs?
  • Which company is conducting major trials for polycystic ovary syndrome drugs?
  • Which companies/institutions are involved in polycystic ovary syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in polycystic ovary syndrome?
Related Reports

Global Hormonal Contraceptive Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Polycystic Ovary Syndrome
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Polycystic Ovary Syndrome
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Polycystic Ovary Syndrome: Epidemiology Snapshot
5.1 Polycystic Ovary Syndrome Incidence by Key Markets
5.2 Polycystic Ovary Syndrome – Patients Seeking Treatment in Key Markets
6 Polycystic Ovary Syndrome: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Polycystic Ovary Syndrome: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Polycystic Ovary Syndrome, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Polycystic Ovary Syndrome Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Polycystic Ovary Syndrome Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Semaglutide 1.34 mg/mL
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Polycystic Ovary Syndrome Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: HRS9531
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Polycystic Ovary Syndrome Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Biological: AlloRx
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Polycystic Ovary Syndrome Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug: Estradiol
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Polycystic Ovary Syndrome, Key Drug Pipeline Companies
14.1 Fujian Shengdi Pharmaceutical Co., Ltd.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Abbott Laboratories
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 AbbVie
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 AstraZeneca Plc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Bristol-Myer Squibb Company
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Pfizer Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Sanofi SA
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us